The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 5, 2003, Pages 351-355

  Lee, Agnes Y Y ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Heparin; Low molecular weight heparin; Neoplasm; Prophylaxis; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; COUMARIN DERIVATIVE; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TICLOPIDINE; TINZAPARIN; WARFARIN;

ABDOMINAL SURGERY; ANTICOAGULATION; BLEEDING; CANCER PATIENT; CANCER RISK; CLINICAL RESEARCH; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; GLIOMA; HEPARINIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LONG TERM CARE; LUNG EMBOLISM; PATIENT SELECTION; RECURRENT DISEASE; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0041737639     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200309000-00002     Document Type: Review

References (20)

1. Mismetti P, Laporte S, Darmon JY, et al.: Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001, 88:913-930.
2. Prandoni P, Lensing AW, Piccioli A, et al.: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100:3484-3488. This is the largest prospective cohort series reporting the incidence of recurrent thrombosis and bleeding in patients with and without cancer.
3. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997, 84:1099-1103.
4. Bergqvist D, Agnelli G, Cohen AT, et al.: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002, 346:975-980. This is the first randomized, controlled trial to examine the efficacy and safety of extending prophylaxis beyond hospitalization in patients undergoing surgery for cancer.
5. Bergqvist D, Agnelli G, Cohen A, et al.: Prolonged prophylaxis against venous thromboembolism with enoxaparin in patients undergoing surgery for malignancy: 1-year survival study. Blood 2002, 100:502a.
6. Rasmussen MS: Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treat Rev 2002, 28:141-144.
7. Eikelboom JW, Quinlan DJ, Douketis JD: Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001, 358:9-15.
8. Hull RD, Pineo GF, Stein PD, et al.: Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001, 135:858-869.
9. Marras LC, Geerts WH, Perry JR: The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000, 89:640-646.
10. Anderson F, Huang W, Sullivan C, et al.: The continuing risk of venous thromboembolism following operation for glioma: findings from the Glioma Outcomes Project. Thromb Haemost 2001, 86(suppl):OC902.
11. Iorio A, Agnelli G: Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000, 160:2327-2332.
12. Goldhaber SZ, Dunn K, Gerhard-Herman M, et al.: Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002, 122:1933-1937.
13. Crandon AJ, Koutts J: Incidence of post-operative deep vein thrombosis in gynaecological oncology. Aust N Z J Obstet Gynaecol 1983, 23:216-219.
14. Maxwell GL, Synan I, Dodge R, et al.: Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 2001, 98:989-995.
15. Meyer G, Marjanovic Z, Valcke J, et al.: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002, 162:1729-1735. This is the first published, randomized trial to compare the efficacy and safety of LMWH with warfarin for the prevention of recurrent venous thrombosis in cancer patients.
16. Lee AYY, Levine MN, Baker RI, et al.: Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in cancer. New Engl J Med 2003, in press. This is the first publication to show superiority of low-molecular-weight heparin dalteparin over oral anticoagulant therapy for secondary prophylaxis in cancer patients with venous thromboembolism.
17. Hull RD, Pineo GF, Mah AF, et al.: A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood 2002, 100:148a.
18. Decousus H, Leizorovicz A, Parent F, et al.: A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998, 338:409-415.
19. Luk C, Wells PS, Anderson D, et al.: Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001, 111:270-273.
20. Kakkar AK, Kadziola Z, Williamson RC, et al.: Low molecular weight heparin therapy and survival in advanced cancer. Blood 2002, 100:148a.